Overview

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
LaNova Medicines Limited
Treatments:
Dexamethasone